Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 161   

Articles published

NVS 91.75 -1.62 (-1.74%)
price chart
Stock Report on Novartis AG (ADR) (NYSE:NVS)
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
European stocks Overview: LyondellBasell Industries NV (NYSE:LYB), Novartis AG ...
Novartis AG (ADR) (NYSE:NVS) was at $93.37 in the last trading session after the stock fell -0.88%. The market capitalization of the company is $252.81 billion with the total outstanding shares of 2.42 billion.
Novartis AG (ADR) (NYSE:NVS) Plans To Provide Cheap Medicines To Poorer Countries
Novartis AG (ADR) (NYSE:NVS) has come up with an initiative that it calls Novartis Access. The program aims to expand access to medicine in poor countries.
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Oversold Stocks To Watch: Novartis AG (ADR) (NYSE:NVS), Sunoco Logistics ...
The following stocks (NYSE:NVS, NYSE:SXL and NYSE:CMI) are oversold as their Relative Strength index (RSI) is below 30. Indeed, the RSI is one of the most popular technical indicators and is computed on the basis of the speed and direction of a stock's ...
Healthcare Stocks Watch List - Novartis AG (NVS), Agilent (A), Vascular ...  Techsonian (press release)
Technical Report on Novartis AG (ADR) (NYSE:NVS)
[Zacks] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx.
Novartis AG (ADR) (NYSE:NVS) Faces a Huge Fine as a Result of Allegations ...
Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).
Novartis AG (ADR) Partners With Amgen, Inc. On Alzheimer's And Migraine
Amgen, Inc. (NASDAQ:AMGN) entered into a two-way partnership deal with Novartis AG (ADR) (NYSE:NVS) on Tuesday, to co-develop the Swiss drug-maker's Alzheimer's drug pipeline, in exchange for Novartis gaining access to Amgen's migraine drug ...
Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs (press release)
Novartis AG (ADR) (NVS) To Acquire Spinifex
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million  Bidness ETC
Novartis to buy privately held Spinifex for $200 mln  Proactive Investors USA & Canada
Novartis AG (ADR) (NVS) Stock Update: September Begins With Multiple Deals And ...
Novartis AG (ADR) (NYSE:NVS) has seen an eventful first week of September. The company struck a partnership deal with biotech giant Amgen, Inc. (NASDAQ:AMGN) and won regulatory approvals for several drugs in both the US and Europe - all during the ...
European stocks on the move: Novartis AG (ADR) (NYSE:NVS), Anheuser Busch ...
Novartis AG (ADR) (NYSE:NVS) declined -0.80% and closed the last trading session at $95.88. Its 52-Week range is from $84.17 to $106.84.